UNBELIEVABLE: Cdtx - The Untold Story

Merck Makes Big Bet On Flu Protection With Cidara Buyout

Merck Co. Inc. (NYSE:MRK) on Friday agreed to acquire Cidara Therapeutics, Inc. (NASDAQ:CDTX) for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion.

Benzinga · Nov 14, 2025

Why Is Cidara Therapeutics (CDTX) Stock Trending Overnight?

Cidara Therapeutics Inc. (NASDAQ:CDTX) shares are trending on Friday.

Benzinga · Nov 14, 2025

Cidara Therapeutics Analyst Says Lead Influenza Candidate Is 'Strategically Attractive'

JP Morgan initiated coverage of Cidara Therapeutics Inc. (NASDAQ:CDTX) on Friday, citing its lead asset, CD388, for influenza, underscoring the game-changing potential of the product and multi-billion dollar potential in the U.S. alone.

Benzinga · Oct 10, 2025

Are These Biotech Stocks a Buy or Sell for August: Bionano Genomics (BNGO) vs. Cidara Therapeutics (CDTX)?

Underpinned by undeniable growth trends of an aging population, breakthrough therapies, and the inelastic demand for healthcare products and medicines, the biotech industry is expected to perform well in the near term. Given this backdrop, let’s compare two biotech stocks, Bionano Genomics (BNGO) and Cidara Therapeutics (CDTX), to determine if…

StockNews.com · Aug 2, 2023

3 Value Stocks With Great Returns

April’s robust labor market and persistently high inflation could strengthen the likelihood of interest rates remaining elevated for an extended period. So, fundamentally strong value stocks CIRCOR International (CIR), Consolidated Water (CWCO), and Cidara Therapeutics (CDTX), which have generated solid returns, could be one’s top picks now. Keep reading.

StockNews.com · May 30, 2023

4 Hyper-Growth Stocks That Could Soar

Coupled with the macroeconomic headwinds, the U.S. debt default crisis and consequent recessionary fears have triggered market volatility. Against this backdrop, quality growth stocks Boston Scientific (BSX), Cardinal Health (CAH), Cidara Therapeutics (CDTX), and Geospace Technologies (GEOS) could be solid buys now. Read on….

StockNews.com · May 24, 2023

4 Biotech Stocks You Don’t Want to Miss out on in 2023

The biotech industry is growing with considerable developments and government initiatives. Given the solid prospects of the industry, fundamentally sound biotech stocks Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Exelixis (EXEL), and Cidara Therapeutics (CDTX) could be excellent buys. Keep reading.

StockNews.com · Mar 24, 2023

3 Dirt-Cheap Stocks to Buy Right Now

Amid easing inflation numbers, the Fed is expected to slow down its rate hike aggression in 2023. Moreover, the stock market might witness a recovery this year. Given the favorable outlook, investors should consider buying dirt-cheap yet quality stocks Ambev (ABEV), VEON (VEON), and Cidara Therapeutics (CDTX) in 2023. Keep…

StockNews.com · Jan 24, 2023

3 Biotech Stocks to Buy for Under $20 Right Now

The need for more advanced biotech research and development has increased amid an aging population and growing medical needs. Investors' sentiment toward biotech stocks has improved significantly over the past months. Given the industry's solid prospects, fundamentally sound biotech stocks Exelixis (EXEL), Innoviva (INVA), and Cidara Therapeutics (CDTX) might be…

StockNews.com · Dec 21, 2022

Read Why HC Wainwright Lowered Price Target On This Small Biotech Stock

U.S. marketing application filing for Cidara Therapeutics Inc's (NASDAQ: CDTX) rezafungin remains on track for mid-2022, setting up a potential early 2023 approval and launch. 

Benzinga · May 12, 2022